Covalent Inhibitors of Kras G12C
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 61/852,123, filed Mar 15, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,227,978 | Covalent Inhibitors of Kras G12C In force · High confidence UsedRemaining | Araxes Pharma LLC | In force | High confidence | ||
| US 9,926,267 | Covalent Inhibitors of Kras G12C In force · High confidence | Araxes Pharma LLC | In force | High confidence | ||
| US 10,273,207 | Covalent Inhibitors of Kras G12C In force · High confidence | Araxes Pharma LLC | In force | High confidence | ||
| US RE50,527 | Covalent Inhibitors of Kras G12C In force · Low confidence | Araxes Pharma LLC | In force | Low confidence | ||
| US 10,919,850 | Covalent Inhibitors of Kras G12C Surrendered on reissue Aug 12, 2025 High confidence | Araxes Pharma LLC | Surrendered on reissue Aug 12, 2025 | High confidence | ||
| Application 19/237,891 | Covalent Inhibitors of Kras G12C Pending Not granted | Araxes Pharma LLC | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Araxes Pharma LLC.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.